The short version
- Why people research itFat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- What the evidence isFDA-approved — as a 5% oral paste for aphthous ulcers, which has nothing to do with why it appears here.
- What to watchCold sores, shingles or other viral infections that return or linger.
How Amlexanox works
Amlexanox inhibits two kinases — TBK1 and IKK-epsilon — and the reason that produces a metabolic effect is one of the most satisfying mechanism chains in this catalog, because it ends at a specific enzyme in the fat cell.
The chain, one step at a time. Obesity produces a chronic inflammatory state involving NF-kappaB signaling, and one consequence is persistent elevation of the non-canonical IkappaB kinases IKK-epsilon and TBK1 in white adipose tissue. Those kinases phosphorylate and activate PDE3B, the major adipocyte phosphodiesterase.
Blocking them raises cAMP and increases metabolic rate in fat tissue.
- Oral
On the goal map: Substrate partitioning & insulin control (Lose fat)
Research on Amlexanox7 evidence notes: clinical, correlative, mechanism
Each note is labeled by the kind of evidence it stands on. Unproven is not ineffective: a missing trial means nobody has run it yet. How the evidence tiers work
Evidence on file: A small pilot in obese type-2 diabetics improved HbA1c and hepatic fat — in responders only.
Human clinical evidence
FDA-approved — as a 5% oral paste for aphthous ulcers, which has nothing to do with why it appears here. That approval establishes human safety by a topical route only.
A phase 2 trial in obese patients with type 2 diabetes tested it orally and reported improved glycemic control and reduced hepatic steatosis — but only in a responder subgroup, roughly half the participants, distinguished by their inflammatory profile at baseline.
A responder-only result in a small trial is a hypothesis about who it works for, not a demonstration that it works.
Correlative data
Almost no metabolic real-world use; it remains largely a research compound outside its dental indication. The trial identified elevated baseline inflammatory markers as the responder signature, which is at least a testable prediction.
How the mechanism reads
Inhibits TBK1 and IKK-epsilon, two kinases induced by obesity-related inflammation that suppress energy expenditure by degrading cAMP signaling in fat tissue.
MechanisticThe interesting claim is directional: these kinases are part of a counter-regulatory brake that switches on with chronic inflammation, so inhibiting them releases a brake rather than pressing an accelerator.
MechanisticThat explains the responder subgroup precisely — if the brake is not engaged, there is nothing to release. It is one of the few compounds here whose mechanism predicts its own non-responders.
Mechanistic
Sources
- Mowers J, et al. Inflammation produces catecholamine resistance in obesity via activation of PDE3B by the protein kinases IKKepsilon and TBK1. eLife 2013 · PMID 24368730
- Xiao QA, et al. Role of IKKepsilon in the Metabolic Diseases: Physiology, Pathophysiology, and Pharmacology. Frontiers in Pharmacology 2022 · PMID 35662709
- Zhao P, et al. The TBK1/IKKepsilon inhibitor amlexanox improves dyslipidemia and prevents atherosclerosis. JCI Insight 2022 · PMID 35917178
- Huh JY, et al. Roles of IkappaB kinases and TANK-binding kinase 1 in hepatic lipid metabolism and nonalcoholic fatty liver disease. Experimental and Molecular Medicine 2021 · PMID 34848839
- You W, et al. Unlocking therapeutic potential of amlexanox in MASH with insights into bile acid metabolism and microbiome. NPJ Gut and Liver 2025 · PMID 40519640
- Hui L, et al. Amlexanox targeted inhibition of TBK1 regulates immune cell function to exacerbate DSS-induced inflammatory bowel disease. Clinical and Experimental Immunology 2024 · PMID 39248363
Amlexanox safety basicsWho should avoid it, what to expect, what to watch
Avoid if
- Active or recurrent viral infection, or immune suppression, because TBK1 carries antiviral interferon signaling.
- Liver disease.
- Type 1 diabetes or insulin use, as its effect on glucose handling is unmapped.
- Allergy to the drug.
- Pregnancy or under 18, where immune-kinase blockade is untested.
What’s expected
- Higher cAMP in fat cells and a modest rise in energy use.
- Lower inflammatory kinase tone, shown in small diabetes trials as better glucose or liver fat in some people.
- Nothing noticeable day to day for most people.
Watch for
- Cold sores, shingles or other viral infections that return or linger.
- Yellow skin or dark urine.
- Palpitations with unusual sweating.
Labs that tell you it’s working
- HbA1c: the diabetes trials used glucose control as the endpoint.
- Insulin (Fasting): inflammation-driven insulin resistance is the target.
- hs-CRP: shows whether kinase blockade lowers systemic inflammation.
- Comprehensive Metabolic Panel: liver enzymes, since fatty liver was an outcome studied.
TBK1 and IKK-epsilon inhibition raises cAMP and energy expenditure; those kinases also run antiviral innate immunity. PMID 24368730 PMID 35917178
Bloodwork to runHow you would know it is working: 7 tests in one order, code CAMERON
A panel picked from how it works and what it can move: the tests, and why each is on it.
Code CAMERON applies automatically. The before and after schedule and how to read the results are in the Skool lesson.
Amlexanox FAQ4 common questions
- Is Amlexanox approved for human use?
- No. Amlexanox is a research compound.
- What is Amlexanox researched for?
- Fat oxidation, appetite and energy regulation, insulin sensitivity and endurance capacity.
- Which labs show whether it's doing anything?
- HbA1c; Insulin; hs-CRP; Comprehensive Metabolic Panel: a baseline before you start and a recheck after. The panel on this page orders them in one cart.
- Where's the full protocol?
- In the Skool lesson for Amlexanox: the protocol, dose and schedule, timing, what to stack, the cycle answer, the bloodwork plan and the cheat sheet. Protocol & dosing live there, not on the public site.



